Projects per year
Personal profile
Headline
ASSOCIATE PROFESSOR | Psychiatry
Biography
Dr. Hillel Grossman is Co-Director of the Clinical Research Core of the Alzheimer's Disease Research Center and Clinical Director of the Mount Sinai Memory and Aging Center. Dr. Grossman is a psychiatrist by training with a focus in geriatric neuropsychiatry and has been involved in designing and conducting clinical studies in Alzheimer's disease. His studies are both observational, e.g. what happens as Alzheimer's progresses and interventional e.g. clinical trials. At present he is the Principal Investigator or Co-Principal investigator on numerous studies of potential treatments or diagnostic tools for Alzheimer's disease. Dr. Grossman has received funding from the NIH, VA and foundations for his investigations of interaction between Alzheimer's and Type II diabetes mellitus and the potential use of a natural insulin sensitizer, NIC5-15, in Alzheimer's disease. Dr. Grossman has also conducted work in the relationship late life depression and cognitive performance in HIV-1 infection.
Fingerprint
Dive into the research topics where Hillel Grossman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 8 Finished
-
Mount Sinai Alzheimer's Disease Research Center
Sano, M., Goate, A., Grossman, H., Haroutunian, V., Hedden, J. C., Robakis, N., Sano, M., Sewell, M. & Zhu, C.
1/05/20 → 28/02/23
Project: Research
-
-
-
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease
Gandy, S. E. & Grossman, H.
National Center for Complementary and Integrative Health
15/09/10 → 30/11/17
Project: Research
-
DEVELOPMENT OF D-PINITOL IN THE TREATMENT OF ALZHEIMER'S DISEASE
National Center for Research Resources
1/03/09 → 31/07/09
Project: Research
-
Agitation in Cognitive Disorders: Use of the National Alzheimer's Coordinating Center Uniform Data Set (NACC-UDS) to Evaluate International Psychogeriatric Association Definition
Sano, M., Zhu, C. W., Neugroschl, J., Grossman, H. T., Schimming, C. & Aloysi, A., Nov 2022, In: American Journal of Geriatric Psychiatry. 30, 11, p. 1198-1208 11 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
Alzheimer’s Disease Neuroimaging Initiative, Jul 2022, In: Nature Aging. 2, 7, p. 616-634 19 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Apathy and Functional Impairment in the Course of Behavioral Variant Frontotemporal Dementia
Zhu, C. W., Grossman, H. T. & Sano, M., 7 Dec 2022, In: JAMA network open. 5, 12, p. E2245656Research output: Contribution to journal › Article › peer-review
Open Access -
Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (Nature Communications, (2020), 11, 1, (411), 10.1038/s41467-019-13962-0)
The Alzheimer Disease Neuroimaging Initiative, Dec 2022, In: Nature Communications. 13, 1, 4006.Research output: Contribution to journal › Comment/debate
Open Access -
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
Alzheimer’s Disease Neuroimaging Initiative (ADNI), Dec 2022, In: Nature Communications. 13, 1, 1495.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations
Press/Media
-
Study Findings from James J. Peters VA Medical Center Broaden Understanding of Alzheimer Disease [Agitation In Cognitive Disorders: Use of the National Alzheimer's Coordinating Center Uniform Data Set (Nacc-uds) To Evaluate International ...]
Judith A. Neugroschl, Corbett Schimming, Mary Sano & Hillel Grossman
15/12/22
1 item of Media coverage
Press/Media
-
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
2/10/18
1 item of Media coverage
Press/Media
-
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol; ADNI3
2/10/18
1 item of Media coverage
Press/Media
-
Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
2/10/18
1 item of Media coverage
Press/Media
-
Development of NIC5-15 in the Treatment of Alzheimer's Disease
2/10/18
1 item of Media coverage
Press/Media